<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>11813114</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Asensio Sánchez, V M</dc:author>
<dc:author>Fernández Concellón, L</dc:author>
<dc:author>Carlos Bejarano, J</dc:author>
<dc:author>Pérez Flández, F J</dc:author>
<dc:description xml:lang="en">PURPOSE To determine if intraocular recombinant tissue plasminogen activator (r-TPA) can be used to treat fibrin blood clots (hyphemas/vitreous) after vitrectomy surgery for diabetic retinopathy. MATERIAL AND METHOD After a retrospective review of medical records, we found 52 patients who underwent vitrectomy for diabetic retinopathy and non-resolving vitreous hemorrhage and/or hyphema during the early postoperative (6 weeks). They were administered r-TPA in dose of 25 microgr/0.1 ml. Hyphemas and vitreous hemorrhages were classified in four grades. RESULTS Tissue Plasminogen Activator was used after vitrectomy surgery in 52 fibrin clotted eyes (52 patients), within the first 3 days post surgery. Vitreous hemorrhages were categorized as grade 2 (21%), grade 3 (67.3%) and grade 4 (11.5%). Hyphemas observed in 18 eyes presented grade 3 (38.9%) and grade 4 (61%). We saw no evidence of intraocular reactions against the r-TPA solution at the dose used in this study. CONCLUSIONS Fibrin blood clots can successfully and effectively be treated with intraocular r-TPA in doses of 25 microgr/0.1 ml (Arch Soc Esp Oftalmol 2002; 77: 7-12).</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2002 Jan </dc:date>
<dc:title xml:lang="es">Hemorragia vítrea postvitrectomía en retinopatía diabética y activador tisular del plasminógeno.</dc:title>
<dc:title xml:lang="en">[Vitreous hemorrhage after vitrectomy in diabetic retinopathy and tissue plasminogen activator].</dc:title>
<dc:publisher>Archivos de la Sociedad Espanola de Oftalmologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
